Absci reported positive interim Phase 1 ABS-201 data and priced a $100 million stock offering to advance development.

Absci Corporation begins dosing patients in the first human trial of ABS-201, an AI-designed antibody for hair loss, reaching clinic in just 24 months.

Absci reported positive interim Phase 1 ABS-201 data and priced a $100 million stock offering to advance development.